Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
dc.contributor.author | Cuzick, J | |
dc.contributor.author | Sestak, I | |
dc.contributor.author | Baum, M | |
dc.contributor.author | Buzdar, A | |
dc.contributor.author | Howell, Anthony | |
dc.contributor.author | Dowsett, M | |
dc.contributor.author | Forbes, J | |
dc.date.accessioned | 2011-02-05T12:07:57Z | |
dc.date.available | 2011-02-05T12:07:57Z | |
dc.date.issued | 2010-12 | |
dc.identifier.citation | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. 2010, 11 (12):1135-41 Lancet Oncol | en |
dc.identifier.issn | 1474-5488 | |
dc.identifier.pmid | 21087898 | |
dc.identifier.doi | 10.1016/S1470-2045(10)70257-6 | |
dc.identifier.uri | http://hdl.handle.net/10541/121326 | |
dc.description.abstract | The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months. | |
dc.language.iso | en | en |
dc.subject | Breast Cancer | en |
dc.subject | Cancer Staging | en |
dc.subject.mesh | Administration, Oral | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Female | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Kaplan-Meier Estimate | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Nitriles | |
dc.subject.mesh | Postmenopause | |
dc.subject.mesh | Tamoxifen | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Triazoles | |
dc.title | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. | en |
dc.type | Article | en |
dc.contributor.department | Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London, London, UK. j.cuzick@qmul.ac.uk | en |
dc.identifier.journal | The Lancet Oncology | en |
html.description.abstract | The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months. |